sovaldi
BMS pulls hep C combo treatment in US
October 7, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Combo, HCV, asunaprevir, daclatasvir, hep C, sovaldi
Bristol-Myers Squibb will not attempt to bring its new combination hepatitis C treatment to the US market given the current …
Sovaldi ‘unaffordable’ says NHS documents
October 7, 2014Medical Communications, Research and Development, Sales and Marketing NHS England, fund, hep C, sovaldi
Senior health officials may have to bar Gilead’s new hepatitis C pill Sovaldi from being funded on the NHS after …
J&J bets $1.75 billion on virology
October 1, 2014Research and Development, Sales and Marketing AL-8176, Alios BioPharma, J&J, JJ, Janssen, sovaldi, viral
Johnson & Johnson has signed a deal to acquire Alios BioPharma, a privately-held company focussed on developing therapies for viral …
Sovaldi combo sees CHMP green light
September 29, 2014Sales and Marketing CHMP, EU, Gilead, HCV, harvoni, hep C, sovaldi
The CHMP is recommending that Gilead’s new combination hepatitis C drug therapy Harvoni should be approved for use across the …
Gilead allows generic prices for Sovaldi
September 16, 2014Manufacturing and Production, Sales and Marketing Gilead, hep C, hepatitis C, sofosbuvir, sovaldi
Gilead will allow Indian generic drug firms to make cheap copies of its new hepatitis C pill Sovaldi in an …
Government rips up blank cheque on cancer drugs
August 28, 2014Medical Communications, Sales and Marketing Cancer Drugs Fund, Kadclya, Roche, avastin, sovaldi
Pharma has priced itself out of the Cancer Drugs Fund as the rising costs of its new oncology treatments sees …
Vertex ditches its once-stellar hep C drug
August 14, 2014Sales and Marketing Gilead, Incivek, Vertex, hep C, sovaldi
Vertex will stop selling its once-blockbuster hepatitis C drug in the US this autumn after being crushed by new therapies. …
NHS England’s Sovaldi fund: opening the floodgates?
July 26, 2014Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDG, NICE, Professor David Haslam, hep C, sovaldi
Whilst seemingly more and more barriers are being erected to slow down the adoption of new medicines, there is a …
FDA approves Gilead’s blood cancer drug
July 24, 2014Research and Development, Sales and Marketing Cancer, FDA, Gilead, blood, follicular lymphoma and small lymphocytic lymphoma, lymphocytic leukaemia, sovaldi, zydelig
The Food and Drug Administration has approved Gilead Sciences new treatment Zydelig (idelalisib) to treat three types of blood cancer. …
Sovaldi scores in HIV patients
July 21, 2014Sales and Marketing Gilead, HIV, JAMA, hep C, hepatitis C, sovaldi
Patients with HIV and hepatitis C virus (HCV) have responded well to a combination of Gilead Sciences’ Sovaldi and ribavirin …
New drugs see J&J sales rise
July 17, 2014Medical Communications, Sales and Marketing J&J, JJ, Q2, hepatitis C, olysio, sovaldi
Johnson & Johnson saw sales rise 9.1% to $19.5 billion year on year on the back of a strong performance …
AbbVie hep C treatment fast-tracked
June 18, 2014Research and Development, Sales and Marketing AbbVie, Abbott, EMA, EU, Gilead, HCV, hep C, sovaldi
The European regulator is to fast-track AbbVie’s oral, interferon-free treatment for adults with chronic genotype 1 (GT1) hepatitis C virus …
NICE rejection looms for Sovaldi
June 16, 2014Sales and Marketing Gilead, NHS, NICE, SMC, hep C, sofosbuvir, sovaldi
In a draft recommendation published today NICE is asking Gilead for more information on its new hepatitis C pill Sovaldi …
Sovaldi hurdles first drug pricing barrier
June 10, 2014Sales and Marketing Gilead, SMC, Scotland, hep C, sofosbuvir, sovaldi
Scotland’s NHS will pay for Gilead’s new hepatitis C pill Sovaldi despite rising concern over its high cost. The Scottish …
Sales forecasts leave Sovaldi top and Januvia lagging
May 23, 2014Sales and Marketing Gilead, Januvia, Merck, diabetes, ep, hep C, sovaldi
Sovaldi has topped analysts’ estimates for future growth but Merck’s big-selling diabetes drug Januvia is falling by the wayside. This …
